Prostate Adenocarcinoma: TransCutaneous Hormones. A randomised-controlled trial of transcutaneous oestrogen patches versus LHRH analogues in prostate cancer
Latest Information Update: 15 May 2024
At a glance
- Drugs Estradiol (Primary) ; Estradiol (Primary) ; Goserelin; Goserelin; Leuprorelin; Leuprorelin; Triptorelin; Triptorelin
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms PATCH
- 13 May 2024 Planned End Date changed from 1 Sep 2024 to 1 Feb 2026.
- 01 Jan 2024 Results from NCT00303784 and NCT00268476 assessing androgen suppression, quality of life and bone health indices and cardiovascular events , published in the Clinical Oncology
- 17 Apr 2023 Status changed from completed to active, no longer recruiting.